Concepedia

Steven J. Hartman

SJ

Statistics

Publications

15

Citations

1K

H-Index

13

Active since

2007

Affiliations

WuXi AppTec (China)(Current)

Charles River Laboratories (United Kingdom)

Oregon State University

Theravance Biopharma (United States)

Ideaya Biosciences (United States)

Steven J. Hartman is an author at WuXi AppTec (China) specializing in medicine, pharmacology, and immunotherapy.

ORCID

Top concepts

Publications per year

2007–2024

15

Publications

15

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Jane Guan, Wei Zhou, Marc Hafner et al. · Cell · 2019 · 215 citations · Full text

, , +8

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake et al. · Journal of Medicinal Chemistry · 2021 · 159 citations

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties

Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake et al. · Journal of Medicinal Chemistry · 2021 · 140 citations

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Jun Liang, Robert A. Blake, Jae H. Chang et al. · Journal of Medicinal Chemistry · 2021 · 130 citations · Full text

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Peter S. Dragovich, Pragya Adhikari, Robert A. Blake et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 102 citations

, , +9

1–5 of 15